Abbott Laboratories income statement & cash flow
In the fiscal year ended Dec 31, 2025, Abbott Laboratories reported net income of $6.52B on revenue of $44.33B. Operating cash flow was $9.57B and capital expenditures were $2.17B, leaving $7.39B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.85B | $27.39B | $30.58B | $31.90B | $34.61B | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B |
| Operating income | $3.03B | $1.56B | $3.65B | $4.53B | $5.36B | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B |
| Net income | $1.40B | $477.00M | $2.37B | $3.69B | $4.50B | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B |
| Diluted EPS | $0.94 | $0.27 | $1.33 | $2.06 | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Operating cash flow | $3.20B | $5.57B | $6.30B | $6.14B | $7.90B | $10.53B | $9.58B | $7.26B | $8.56B | $9.57B |
| Capital expenditures | $1.12B | $1.14B | $1.39B | $1.64B | $2.18B | $1.89B | $1.78B | $2.20B | $2.21B | $2.17B |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | — | 18.2% | 14.7% |
| Dec 2024 | — | 16.3% | 31.9% |
| Dec 2023 | — | 16.2% | 14.3% |
| Dec 2022 | — | 19.2% | 15.9% |
| Dec 2021 | — | 19.6% | 16.4% |
Source: SEC EDGAR XBRL company facts for CIK 1800 (raw data). Most recent filing in this dataset: 10-Q filed Apr 29, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.